Brief: Immunome doses first patient in early-stage trial of its experimental cancer treatment
10/03/2025 12:23
March 10 (Reuters) - Immunome Inc IMNM.O: IMMUNOME DOSES FIRST PATIENT IN PHASE 1 TRIAL OF IM-1021, A ROR1-TARGETED ADC Source text: nBw2fTJV6a Further company coverage: IMNM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage